PURPOSE: The transcriptional cofactor yes-associated protein (YAP) is activated in primary liver cancers (PLCs). YAP is canonically inhibited through serine 127 (S127) phosphorylation via the Hippo pathway but activated by phosphorylation at tyrosine 357 (Y357) by SRC family kinases. Due to liver plasticity, PLCs can originate from different cell types. However, it is unknown whether YAP activation favors tumorigenesis from specific cells of origin or promotes lineage commitment during tumorigenesis. This study investigates how YAP Y357 phosphorylation influences tumor phenotype and cell of origin. METHODS: C57BL/6 mice underwent biliary transfection with myr-AKT and YAP S127A (YAP-S) or YAP S127A/Y357F (YAP-SY). RNA sequencing and pathway analysis were performed on tumors. To determine the cell of origin, tumors were generated in lineage-tracing mice by biliary transfection or hydrodynamic tail vein injection. Two tumor-derived cell lines were isolated and characterized. RESULTS: YAP-S mice developed more frequent intrahepatic cholangiocarcinoma (iCCA), whereas a shift to hepatocellular carcinoma (HCC) was identified in YAP-SY mice. Transcriptome analysis revealed differential activation of pathways linked to this phenotypic switch. Lineage tracing demonstrated iCCA originated from cholangiocytes and HCC from hepatocytes in the biliary transfection, whereas iCCA originated from hepatocytes in the hydrodynamic tail vein injection. Two novel, transplantable syngeneic cell lines with mixed HCC/iCCA features were established. Tumors and cell lines commonly exhibited differential TGF-β signaling. CONCLUSIONS: YAP Y357 phosphorylation modifies the tumor phenotype and the cell of origin in liver cancer models. Differential TGF-β signaling suggests a potential therapeutic avenue for iCCA and mixed tumors. CLINICAL TRIAL NUMBER: Not applicable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13402-025-01133-x.
The oncogenic potential of YAP requires Y357 phosphorylation in cholangiocytes but not in hepatocytes.
阅读:3
作者:Aksu Muhammed Dogukan, Millender Jayla T, McCabe Chantal E, Watkins Ryan D, Yonkus Jennifer A, Buckarma EeeLN H, Werneburg Nathan W, O'Brien Daniel R, Graham Rondell P, Gores Gregory J, Smoot Rory L, Conboy Caitlin B
| 期刊: | Cellular Oncology | 影响因子: | 4.800 |
| 时间: | 2025 | 起止号: | 2025 Dec 24; 49(1):4 |
| doi: | 10.1007/s13402-025-01133-x | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
